MetaCap

Fennec Pharmaceuticals (FENC) vs ProKidney (PROK)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Fennec Pharmaceuticals (FENC) has outperformed ProKidney (PROK) over the past year, gaining 66.1% versus a loss of 52.5%. Over five years, FENC leads with a +35.8% price change compared with -89.5% for PROK. Fennec Pharmaceuticals is the larger company by market cap ($462.1 million vs $415.2 million), about 1.1 times the size, while ProKidney is growing revenue faster (+1075.0% vs -6.1%).

Fennec Pharmaceuticals converts more of its revenue into profit, with a net margin of -21.8% versus -7725.2%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

FENC+66.12%PROK-52.51%
+79%+10%-59%
Nov 21, 20251 yearNov 20, 2026
FENC+33.23%PROK-89.52%
+40%-30%-100%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

FENC versus PROK key metrics
MetricFENCPROK
Share price$13.09$1.04
Market cap$462.14M$415.21M
1-day change-2.68%-1.89%
YTD return+70.00%-53.57%
1-year return+66.12%-52.51%
5-year return+35.79%-89.49%
P/E ratio (TTM)436.33—
Forward P/E12.47—
EPS (TTM)$0.03$-0.61
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$44.64M$893.00K
Revenue growth (YoY)-6.09%+1075.00%
Net income (latest FY)$-9.74M$-68.99M
Operating margin-14.07%-18477.83%
Net margin-21.82%-7725.20%
52-week high$13.85$2.65
52-week low$5.65$0.87
Distance from 52-week high-5.49%-60.75%
Analyst consensusstrong_buybuy
Avg. price target upside+34.45%+525.00%
Average volume220.87K1.44M
Shares outstanding35.31M209.63M
Employees35231
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • FENC has outperformed PROK by 118.6 percentage points over the past year.
  • Fennec Pharmaceuticals is more profitable, keeping -21.8 cents of every revenue dollar as net income versus -7725.2 cents for ProKidney.
  • ProKidney grew revenue faster in its latest fiscal year (+1075.00% vs -6.09%).

About Fennec Pharmaceuticals

FENC stock →

Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 35 employees

About ProKidney

PROK stock →

ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 231 employees

FENC vs PROK FAQ

Which is bigger, Fennec Pharmaceuticals or ProKidney?

Fennec Pharmaceuticals (FENC) is larger, with a market capitalization of $462.14M compared with $415.21M for ProKidney (PROK).

Which stock has performed better over the past year, FENC or PROK?

FENC returned +66.12% over the past 12 months, compared with -52.51% for PROK (price return, excluding dividends). Past performance does not predict future results.

Are Fennec Pharmaceuticals and ProKidney in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons